Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | TPMT | P51580 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21079189 | 0.92 | PDE4A (0.52) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL7362652 | 0.92 | PDE4A (0.52) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL1015345 | 0.91 | CA12 (0.73) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL3924278 | 0.91 | CA12 (0.73) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL28118006 | 0.88 | KMT2A (0.50) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL28846281 | 0.87 | TSHR (0.69) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL7089045 | 0.87 | TSHR (0.65) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL2543398 | 0.85 | KMT2A (0.55) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL11672654 | 0.85 | HTT (0.66) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL9005609 | 0.85 | TTR (0.56) | KMT2ACA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874722-B1 | HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF | AMOREPACIFIC CORP (KR) | 2015-04-08 | — | — | EP | disclosed |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| CN-1747929-B | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor | CHEMOCENTRYX INC | 2010-04-28 | — | — | CN | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1606251-B1 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | CHEMOCENTRYX INC (US) | 2009-04-08 | — | — | EP | disclosed |
| US-7485750-B2 | Hydroxamic acid derivatives and the preparation method thereof | AMOREPACIFIC CORPORATION (KR) | 2009-02-03 | — | — | US | disclosed |
| US-20080242730-A1 | Hydroxamic Acid Derivatives and the Preparation Method Thereof | AMOREPACIFIC CORPORATION (KR) | 2008-10-02 | — | — | US | disclosed |
| EP-1874722-A1 | HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF | Amorepacific Corporation (KR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006118380-A1 | HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF | AMOREPACIFIC CORPORATION (KR) | 2006-11-09 | — | — | WO | disclosed |
| CN-1747929-A | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor | CHEMOCENTRYX INC (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1606251-A2 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | ChemoCentryx Inc (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040171655-A1 | Inhibitors of human tumor-expressed CCXCKR2 | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004058705-A2 | INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR | CHEMOCENTRYX (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242730-A1 | Hydroxamic Acid Derivatives and the Preparation Method Thereof | COL14A1, CUTA, COL2A1 | KMT2A 1541/4885CA12 2137/4885CA1 1005/4885 |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CCL2, CCR2, CXCR2 | KMT2A 3167/4885CA12 412/4885CA1 721/4885 |
| US-20040171655-A1 | Inhibitors of human tumor-expressed CCXCKR2 | CCL2, CCR2, CXCR2 | KMT2A 3167/4885CA12 412/4885CA1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.